Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective faithfully but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV have been closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last several shares of mine. My first CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set away the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire employment interview that I came away with an inadequate impression of the company.

Irony of irony, the poor opinion of mine of the company has grown steadily, although the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the know-how and connected intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) plus the very first brand new drug program endorsement ($5 million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it’s this single therapy in addition to a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active organization with diverse interests albeit centered on leronlimab, several illness sorts, multiple delivering presentations and multiple publications.

Could all this be smoke cigarettes and mirrors? That’s a question I have been asking myself through the very start of my interest in this particular business. Judging by the multiples of a huge number of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or possibly some could say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *